Cancer AI Startup Paige Secures $45M to Bring Diagnostic Tools to Market
Paige raises $45 million in new funding to advance its AI-driven cancer pathology platform toward FDA approval. The startup leverages a massive database of medical slides from Memorial Sloan Kettering to improve disease detection.
Paige raises $45 million in a new funding round led by Healthcare Venture Partners to advance its artificial intelligence platform for cancer pathology. The startup plans to use this capital to pursue FDA approvals for its biomarker and prognostic tools while exploring commercial opportunities within the biopharmaceutical industry. Despite its significant financial backing, the company does not yet have any commercial products on the market.
The technology behind Paige originates from the Memorial Sloan Kettering Cancer Center, giving the startup exclusive access to a massive database of 25 million pathology slides. This extensive dataset is a crucial training ground for its machine learning algorithms, ensuring the AI system learns from one of the world's largest and most diverse repositories of cancer pathology data.
Valued at approximately $220 million following this latest investment, Paige benefits from the expertise of Dr. Thomas Fuchs, a pioneering figure in computational pathology. By applying advanced machine learning to map the complex mutations and progression of cancer, the company aims to ultimately transform how doctors diagnose and treat the disease.